The Election Can't Come Soon Enough For Biotechs
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
Exclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics' Story
Edward Nash Recent News
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen
Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust
Zafgen Controversy Means Stock Is Worth $25 Now, Notes SunTrust
SunTrust's 5 Biotech Picks For The Next 6 Months
UPDATE: Cowen & Company Upgraded Ironwood Pharmaceuticals